Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of αvβ3-antagonists in rat: Limited role of P-glycoprotein

Xenobiotica

Volumn 32, Issue 3, 2002, Pages 207-220

  Prueksaritanont, T ^a   Meng, Y ^a   Ma, B ^a   Leppert, P ^a   Hochman, J ^a   Tang, C ^a   Perkins, J ^a   Zrada, M ^a   Meissner, R ^a   Duggan, M E ^a   Lin, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 OXO 3 [3 (5,6,7,8 TETRAHYDRO 1,8 NAPHTHYRIDIN 2 YL)PROPYL]PYRROLIDIN 1 YL] 3 QUINOLIN 3 YLPROPANOIC ACID; GLYCOPROTEIN P; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DIASTEREOISOMER; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STRUCTURE; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIPID SOLUBILITY; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; RAT;

ANIMALS; AREA UNDER CURVE; BILE; BLOOD PROTEINS; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INTESTINAL ABSORPTION; MALE; MICE; MICROSOMES, LIVER; NAPHTHYRIDINES; P-GLYCOPROTEIN; PROTEIN BINDING; PYRROLIDINES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VITRONECTIN; STEREOISOMERISM; VERAPAMIL;

ANIMALIA;

EID: 18344386014     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110094403     Document Type: Article

References (31)

1. Intestinal drug absorption and metabolism. I. Comparison of methods and models to studying physiological factors of in vitro and in vivo intestinal absorption
2. Noncompartmental determination of the steady-state volume of distribution
3. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice
4. Clinical pharmacokinetics of ibuprofen. The first 30 years
5. Effect of the mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice
6. Tissue distribution of the multidrug resistance protein
7. Pharmacology of drugs that alter multidrug resistance in cancer
8. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance
9. Alpha (v) beta (3) integrin antagonists as inhibitors of bone resorption
10. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2)
11. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells
12. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
13. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs
14. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates
15. 3 (the vitronectin receptor)
16. Expression and localization of multidrug resistant protein mrp2 in rat small intestine
17. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites
18. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: Molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs
19. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318: Roles of efflux and metabolism
20. Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer
21. Disruption of the mouse mdr1a P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs
22. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
23. The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells
24. The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples
25. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
26. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
27. Comparison of disposition parameters of quinidine and quinine in the rats
28. The quinoline-based drug N-{4-[1-hydroxy-2(dibutylamino)ethyl]quinolin-8-yl}-4-azadosalicylamide, photoaffinity labels the multidrug resistance protein (MRP) at a biologically relevant site
29. Reversal of MRP mediated doxorubicin resistance with quinoline based drugs
30. In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results
31. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice